Imatinib Grindeks

Imatinib, the active ingredient in Imatinib Grindeks, is a tyrosine kinase inhibitor presented as an oral formulation for systemic use. It is indicated for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors in adult patients and works by targeting specific cellular pathways that drive cancer growth.

GNH USA supplies Imatinib Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable global logistics.

Imatinib is used to target abnormal tyrosine kinase signaling in certain hematologic and solid tumors.

- Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and achieves hematologic and cytogenetic remission. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth and improves progression‑free survival in patients with KIT‑positive disease. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission when combined with chemotherapy.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the ankles. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiotoxicity: decreased left ventricular ejection fraction. - Severe neutropenia: marked reduction in neutrophil count.

Before initiating therapy, clinicians should consider several safety measures.

- Monitor blood counts: regular CBC to detect cytopenias. - Assess liver function: periodic LFTs for hepatotoxicity. - Evaluate cardiac function: echocardiogram if signs of heart failure. - Avoid concomitant strong CYP3A4 inhibitors: may increase plasma levels. - Pregnancy: use only if potential benefit justifies risk; data limited. - Store at ambient temperature below 25°C: keep in original container, protect from moisture.

Imatinib interacts with several medicines that can alter its exposure or toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can raise imatinib exposure. - CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce efficacy. - Antacids containing aluminum or magnesium: may affect absorption.

Moderate Interactions (Monitor Closely): - Acid‑reducing agents (e.g., omeprazole): may modestly decrease plasma levels. - Warfarin: imatinib may enhance anticoagulant effect, monitor INR. - Concomitant chemotherapy agents (e.g., cytarabine): increased risk of myelosuppression.